Early Detection of Temporal Lobe Epilepsy: Identification of Novel Candidate Genes and Potential Biomarkers Using Integrative Genomics Analysis
Vishruth Nagam
BioScience Project, Wakefield, USA.
DOI: 10.4236/ojgen.2020.104006   PDF   HTML   XML   160 Downloads   471 Views  


Currently afflicting more than 50 million people worldwide, epilepsy is the spectrum disorder characterizing seizures that occur without other plausible medical explanations. Temporal lobe epilepsy (TLE) is one of the most common forms of epilepsy. Current clinical methods; including MRI scans, EEG tests, and doctor visits; can take upwards of several months to confirm a TLE diagnosis; during this time, patients may experience additional seizures and are at an increased risk for other psychiatric disorders. The purpose of this study is to identify candidate genetic biomarkers to facilitate the earlier detection and diagnosis of TLE through gene-based testing (e.g., genomic heatmap analysis or genetic and/or microarray testing). It was hypothesized that potential biomarkers could be identified by analyzing genes that are normally significantly overexpressed in the temporal lobe relative to the gray matter. Statistical and functional analysis was performed on significantly overexpressed genes (≥3.000 fold change) in the gene expression profiles of four donors without epilepsy. The experimental-evidence-based STRING protein interactions analysis showed associations between genes found in DAVID keyword search and other genes facilitating network interconnectivity. After evaluation of the genes’ STRING enriched functions, changes in the expression of the genes CAMK2A, NPY, DLG4, MEF2C, and MAPK7 were concluded to be potential biomarkers for TLE, confirming the original hypothesis. Specifically, the identification of MEF2C and MAPK7 for this purpose is relatively novel in the fields of bioinformatics and neurogenetics. Future work includes investigating the utility of the candidate genes in real-world gene-based diagnostic methods.

Share and Cite:

Nagam, V. (2020) Early Detection of Temporal Lobe Epilepsy: Identification of Novel Candidate Genes and Potential Biomarkers Using Integrative Genomics Analysis. Open Journal of Genetics, 10, 65-81. doi: 10.4236/ojgen.2020.104006.

1. Introduction

When electrical activity in the brain is abnormal or irregular for a brief period of time, events called seizures can result [1]. Seizures take place suddenly and last from seconds to over five minutes [1] [2]. A person may experience changes in their behaviors, body movements, and level of awareness (consciousness) [1] [2]. Seizures can also come with other psychiatric or intellectual problems, including suppression of dendritic growth, which can impair learning and certain aspects of emotion [2].

There are several types of seizures, classified based on the affected areas of the brain. Occurring on both sides (hemispheres) of the brain, generalized seizures include petit mal or absence seizures (e.g., cause few seconds of staring or rapid blinking) and grand mal or tonic-clonic seizures (e.g., make the person cry out loudly, collapse, shake, or even lose consciousness) [2]. Focal seizures are the most common form of seizures (most common form in adults and one of the most common forms in children) and are localized to one area of the brain [2]. Secondary generalized seizures begin in a single brain region, but spread to both hemispheres of the brain to become generalized seizures [2].

Epilepsy is a condition that someone is diagnosed with when more than one such seizure occurs without any possible explanation by an underlying, nonpermanent medical condition [2]. More than 50 million people have epilepsy worldwide [3]. Having many possible causes, epilepsy is thus considered, not a single disorder, but a spectrum [1] [2]. In addition, epilepsy is more common in infants ages 1 and below and in seniors ages 65 and above, which could possibly be attributed to comorbid neural phenomena (tumors, strokes, etc.) [1].

TLE is the most common form of focal epilepsy, accounting for focal seizures in the temporal lobe [1]. The temporal lobes lie by the ears, on the sides of the brain, and are involved in speech and language interpretation and production, visual and auditory processing, and involuntary or unconscious responses (e.g., hunger and sexual arousal) [1] [2]. In most cases, TLE can even further be localized to the mesial (i.e., medial or inner) or lateral (i.e., outer) regions of the temporal lobe. Nearly 80 percent of temporal lobe seizures can be attributed to mesial TLE, which often originate in the hippocampus or nearby areas [3]. About 75 percent of TLE cases can be traced to specific causes, including traumatic brain injuries, brain inflammation, and genetic mutations or factors [1].

Utilizing gene expression as an indicator of the presence of neurological disorders and conditions is already an established practice [4]. However, in clinical settings, TLE is currently diagnosed with a combination of magnetic resonance imaging (MRI) scans (to detect changes in the temporal lobe), electroencephalogram (EEG) tests (to reveal abnormal neuronal electrical activity), and patients’ descriptions of symptoms [3]. This process can take upwards of several months after symptoms first appear. During this time, patients may experience additional seizures and are at an increased risk for anxiety, depression, and other psychiatric disorders [5]. It is thus important to diagnose TLE before patients’ symptoms worsen and susceptibility to other conditions increases.

In this study, earlier diagnosis of TLE is proposed using genomic heatmap analysis or genetic and/or microarray testing. Changes in gene expression could suggest potential genetic causes of TLE, indicate the presence of TLE in an individual before symptoms manifest, and allow for antiepileptic treatment to ease the onset of TLE. A previous study reported that a lack of the GABA(B[1])gene; which encodes the subunit receptor 1 of the gamma-aminobutyric acid (GABA) receptor subtype B and facilitates the inhibitory postsynaptic effects of GABA, the most prominent inhibitory neurotransmitter in the central nervous system (i.e., brain and spinal cord); was associated with TLE in mice [6]. Other susceptibility genes and potential biomarkers for TLE include PDYN (prodynorphin) and the ε4 variant of APOE4 (apolipoprotein E) [7].

The purpose of this project is to observe and examine gene expression patterns in the temporal lobe in order to identify candidate genes for TLE. It is hypothesized that certain genes normally significantly overexpressed in the temporal lobe compared to in the gray matter—as revealed through genomic heatmaps—could potentially be genetic biomarkers for TLE, while reflecting biological functions related to TLE.

2. Methods

The Allen Human Brain Atlas by the Allen Institute for Brain Science is a database that was used as the primary source for the gene expression data concerning the temporal lobe [8]. Heatmaps generated from microarray surveys of neural tissue that was donated to the Allen Institute for Brain Science were analyzed for the gene expression data of interest. A differential search was conducted comparing the gene expression in the temporal lobe to that in the gray matter. The data, released in 2010 and last updated in 2013, was obtained from four different donors (H0351.2001, H0351.1009, H0351.1012, and H0351.1015) between 18 and 68 years of age and with no known history of neuropsychiatric or neurological conditions, as gene expression data from individuals with epilepsy was not available in this database (see “Limitations and Future Directions”) [8]. Genes with a fold change of 3.000 or greater were collected for further statistical analysis.

The Venny 2.1 software was used to identify genes common to the four individual donors’ gene lists [9]. The data was visually depicted with a Venn diagram.

The Google Sheets software was used to identify the top twenty genes with the highest fold change values in the gene lists of the four individual donors. The data from the four gene lists was visually displayed in four bar graphs, with each bar graph corresponding to a gene list from a single donor. The software was also used to conduct further statistical analysis (i.e., variance and other common statistical values for the fold change values of the gene lists).

PythonAnywhere is an online integrated development environment utilizing the Python programming language [10]. It was used as a tool for the keyword search in DAVID, which is an online bioinformatics resource developed by the Laboratory of Immunopathogenesis and Bioinformatics [11]. Genes involved in functions associated with epilepsy were identified with the DAVID keyword search.

The Gene Ontology is a bioinformatics resource used to classify the genes common to the four donors (as determined through Venny 2.1) by the three domains of gene ontology: Molecular Function, Cellular Component, and Biological Process [12]. Molecular Function refers to the molecular activities that the gene product performs. Cellular Component concerns where in the cell or in what cellular structures the gene product functions. Biological Process refers to the broader, overarching processes that the gene product helps to accomplish.

The STRING Database was used to construct protein interaction networks based on genetic data to find candidate genes for TLE. It was also used to identify other genes, interactions, and pathways of interest. The first shell and, if needed, the second shell were selected to have a maximum of fifty and ten interactors, respectively. The confidence level was set at medium (0.400) to ensure that enough interactions were generated for analysis. Of the different levels of evidence, ranging from theoretical (least valid) to experimental (most valid), only experimental active interaction sources were used to generate the interactions.

3. Results and Discussion

3.1. Heatmap Analysis

The heatmap is a technique that was used to visualize the microarray values for the gene expression profiles of the four donors mentioned (refer to Figure 1). The bar at the top of the heatmap is of a unique color specific to each donor, indicating the donor that has been selected. The bar below represents the different brain regions in the heatmap. Each row and column of the heat map represent a particular gene and a tissue sample, respectively. The color of each box is indicative of the z-score over a probe ranging from red (z-score of +3 and above) to black (z-score of 0) to green (z-score of −3 and below).

Figure 1. Allen Human Brain Atlas heatmap of Donor H0351.2001 generated by a differential search comparing gene expression in the temporal lobe to that in the gray matter.

The gene count varied noticeably among the donors. Donor H0351.2001 had 145 genes with a fold change greater than 3.000, while Donors H0351.1009, H0351.1012, and H0351.1015 had 184, 246, and 330 such genes, respectively.

3.2. Venny 2.1 Analysis

The venn diagram (refer to Figure 2) shows the common genes between, as well as the genes unique to, the gene lists of the four individual donors. 76 (29.3%) genes were identified to be commonly expressed in the temporal lobe amongst all four donors.

3.3. Bar Graphs

The bar graphs (refer to Figure 3) show the twenty genes with the highest fold change values from each of the four individual donors. The x-axis displays the symbols of the genes, and the y-axis displays the fold change values. Ten genes (TMEM155, LY86-AS1, NPPA, PKD2L1, A_24_P895687, GDA, FOXG1, CCK, A_32_P105747, and THEMIS) appeared in all four lists of the twenty genes with the highest fold change values. Genes that appeared in exactly three of the four lists include NRGN, HSPB3, SLC30A3, and A_32_P21848.

3.4. Statistical Analysis

The statistical analysis (refer to Table 1 for a full list of statistical values for each donor) for the 300 genes with the highest fold change values shows that the mean fold change ranges from 3.26 to 4.47 across the gene lists. Lower mean fold changes tend to be associated with lower minimum and maximum fold changes; however, from a qualitative standpoint, the minimum fold changes, spanning within a range of 2.43 to 3.11, did not differ greatly from donor to donor. The variance values amongst the donors are also relatively similar to each other, ranging from 0.85 to 2.35. Standard deviation appears to be quite similar amongst the donors, between 0.92 and 1.53.

Figure 2. Venn diagram generated through Venny 2.1 depicting the common genes expressed in the temporal lobe between the four individual donors.

Figure 3. Bar graphs generated through Google Sheets depicting the fold change values of the top twenty genes in the gene lists of each of the four individual donors.

Table 1. Statistical analysis table for the gene lists of the four individual donors. The 300 genes with the highest fold change values for each donor were used.

3.5. DAVID Keyword Search

In the keyword analysis, the genes common to the four individual donors’ gene lists were used to determine possible candidate genes for TLE. Within the DAVID bioinformatics database, the “GOTERM_BP_DIRECT,” or biological processes, section of the Functional Annotation Tablefor the Homo sapiens species was used to find genes (refer to Figure 4 and Figure 5 for examples of the search methods used) associated with functions related to TLE.

The genes of interest (MEF2C, HTR2A, SERPINF1, etc.) tend to be related to excitatory postsynaptic potentials (i.e., the increase in a postsynaptic cell’s membrane potential resulting from the diffusion of sodium ions into the cell through ligand-gated sodium ion channels), inflammatory responses, and the neurotransmitters glutamate (excitatory) and GABA (inhibitory) [13]. In light of the known positive effects of a high-fat, low-carbohydrate (ketogenic) diet on remediating epilepsy symptoms, some genes were associated with saccharides and lipids as well (refer to Table 2 for a full list of keywords used and the corresponding genes of interest) [2].

Figure 4. Python script used for the keyword search in the DAVID bioinformatics database, with an example containing the search word “glutamate” shown above.

Figure 5. Example of a keyword search in the DAVID Functional Annotation Table for the word “excitatory” (highlighted in orange).

Table 2. Keywords used in the search, along with the corresponding genes of interest. Some keyword searches, including “electric” and “spasm,” did not yield in any genes that were common amongst the four individual donors.

3.6. Gene Ontology Analysis

Of the 76 genes that were commonly expressed amongst the four donors, 16 were unmapped in the Gene Ontology database (refer to Figure 6), one was attributed to multiple PANTHER ID’s, and the other 60 did have uniquely mapped ID’s in the database. Hence, the 61 genes with ID’s in the database were used in the Gene Ontology classification.

Concerning Molecular Function (refer to Figure 7 for the complete pie charts and relative proportions of genes placed in each category), 21 genes (34.4%) were involved in “binding,” while 9 genes (14.8%) were placed in the “catalytic activity” category. Several genes that were in the “binding” category (e.g., MEF2C and HTR2A), in the “catalytic activity” category (e.g., ADCY2), and in both of these categories (e.g., CAMK2A and SERPINF1), were also found to be associated with TLE through the DAVID keyword search.

The Cellular Component revealed that the “cell part” and “cell” categories each consisted of 27 genes (44.3%), the “organelle” category comprised 16 genes (26.2%), and the “membrane” category consisted of 15 genes (24.6%). The “cell part” and “cell” categories shared all 27 of their genes with each other. Though the “organelle” and “membrane” categories had a majority of their genes in common, the genes of interest found through the DAVID search were localized to either one of the categories. For example, MEF2C was only classified in the “organelle” category, and HTR2A and CAMK2A were only classified in the “membrane” categories.

In Biological Processes, the most common categories were “cellular process” and “biological regulation,” with 22 (36.1%) and 19 (31.1%) genes, respectively. Within the “cellular process” category, 10 (45.5%) and 9 (40.9%) genes were associated with the “cellular metabolic process” and “cell communication” categories, respectively. These two findings suggest a possible connection to the abnormal neural excitation that is characteristic of TLE [1] [2] [3].

3.7. STRING Gene-to-Gene and Protein Interactions

Of the 10 unique genes that were commonly expressed amongst the four donors and appeared in the keyword search, ADCYAP2 did not have data relevant to Homo sapiens in the STRING Database. Hence, the other nine genes were used to conduct the protein interaction analysis.

A protein interaction network (refer to Figure 7) was generated with the input genes ADCY2,HTR2A,MEF2C,CAMK2A,HTR4,SLC22A5,SERPINF1,NPY,and PRKCI. The network contained 50 and 10 interactors in the first and second shells, respectively, and its clusters centered on the following genes (in decreasing order of cluster size, measured by number of direct interactions): PRKCI (21 first shell interactions), CAMK2A (15 first shell interactions), PSMD1 (2 first shell interactions and 8 second shell interactions), MEF2C (8 first shell interactions), NPY and ADCY2 (each with 2 first shell interactions), SERPINF1 and HTR2A (each with 1 first shell interaction), and HTR4 and SLC22A5 (each with no interactions).

Figure 6. Molecular Function, Cellular Component, and Biological Process pie charts, respectively, generated through The Gene Ontology and the PANTHER classification system.

Figure 7. Protein interactions network generated through the STRING Database. The genes found through the keyword search (ADCY2, HTR2A, MEF2C, CAMK2A, HTR4, SLC22A5, SERPINF1, NPY, and PRKCI) were inputted and are boxed in black. The thickness of lines represents the relative strength of experimental support and validation. First shell interactors and second shell interactors are shown in colored nodes and white nodes, respectively. Empty nodes and filled nodes represent that the 3-dimensional structure is unknown and known or predicted, respectively.

Note that PSMD1 and the input gene PRKCI were linked through a direct first shell interaction and that 8 of the 10 total second shell interactions were linked to PSMD1. Also, several members of the mitogen-activated protein kinase (MAPK) family, including MAPK7 and MAPK14, play an integral role in linking different clusters to each other. In addition, PSMC5 is the only one of the second shell interactors that has a direct link to an input gene (CAMK2A). DLG4 and members of the proteasome regulatory subunit group (e.g., PSMD1 and PSMC5) seem to link several clusters together as well.

Because the limits of STRING may have constrained the number of network edges shown, another network analysis was conducted with only the original input genes that were part of smaller clusters (NPY, ADCY2, SERPINF1, HTR2A, HTR4, and SLC22A5). This was done to reveal any network edges and interactions that may have not been displayed in Figure 7.

The second protein interaction network (refer to Figure 8) revealed that HTR2A was indirectly associated with ADCY2 through several members of the guanine nucleotide-binding protein subunit group (e.g., GNAI1). However, NPY, SERPINF1, HTR4, and SLC22A5 did not display any new or different interactions than in Figure 7. Given that the cluster centered around HTR2A contained members of the MAPK family (MAPK1 and MAPK3), another protein network analysis was conducted to investigate any other possible proteins interactions between HTR2A, ADCY2, and the original input genes most directly associated with the MAPK family (PRKCI, CAMK2A, and MEF2C), as revealed in Figure 7.

Due to the display limits of STRING, two separate networks were generated, with one (refer to Figure 9(a)) having HTR2A, ADCY2, CAMK2A, and MEF2C as input genes and the other (refer to Figure 9(b)) replacing CAMK2A with PRKCI. Figure 9(a) suggests an indirect linkage between HTR2A and CAMK2A through GNAO1 and GNAI1, members of the guanine nucleotide-binding protein subunit group. There are also indirect linkages between HTR2A and MEF2C through MAPK14 (Figure 9(a)) and between HTR2A and PRKCI through MAP2K1 (Figure 9(b)), confirming the earlier prediction that HTR2A may have additional interactions through MAPK’s.

Figure 8. STRING protein interaction network with NPY, ADCY2, SERPINF1, HTR2A, HTR4, and SLC22A5. Refer to Figure 7 for black boxes, line thickness, protein color, and node filling meanings.


Figure 9. (a) STRING protein interaction network with CAMK2A, HTR2A, ADCY2, and MEF2C. Refer to Figure 7 for black boxes, line thickness, protein color, and node filling meanings. (b) STRING protein interaction network with PRKCI, HTR2A, ADCY2, and MEF2C. Refer to Figure 7 for black boxes, line thickness, protein color, and node filling meanings.

In summary, the STRING Database protein interaction analysis revealed that potential candidate genes for TLE may be, not only the genes generated through the DAVID keyword search, but also interconnecting or linking genes (MAPK7, MAPK14, MAP2K1, PSMD1, PSMC5, DLG4, GNAO1, and GNAI1). This calls for a reanalysis of each gene’s specific functions as they relate to TLE in order to identify accurate candidate biomarkers (refer to Table 3 for a full list of genes and their respective functions as shown in STRING). Only the genes with the most relevant functions will be discussed below (some genes have also been disregarded due to the lack of specificity in their enriched functions).

Table 3. Candidate genes found through the STRING protein interactions analysis listed with their corresponding STRING enriched functions.

According to the STRING enriched functions, CAMK2A is involved in the NMDAR signaling complex at excitatory synapses and induces increased activation of the FoxO3 transcription factor (promotes apoptosis of damaged neurons) in response to epileptic seizures; this corresponds to previous findings that CAMK2A overexpression is correlated with the onset of hippocampal seizures (deep in the temporal lobe), suggesting its candidacy as a TLE biomarker [14] [15]. MEF2C seems to play an integral role in regulating hippocampal excitatory synaptogenesis; furthermore, the fact that, in the donors (who had no history of epilepsy), MEF2C is significantly overexpressed (>3.000 fold change) in the temporal lobe compared to in the gray matter underscores MEF2C’s important role in preventing abnormal neocortex activity [16]. The identification of NPY as a candidate TLE biomarker corresponds to previous work that shows the correlation between NPY’s neuroprotective effects and its overexpression in individuals with TLE, possibly as a defense mechanism [17]. Relatively few studies have reported MAPK7 as a potential TLE biomarker; however, MAPK7 contributes to the phosphorylation-dependent degradation of MEF2C, suggesting that overexpression of MAPK7 may be linked with the onset of TLE and that underexpression of MAPK7 may be associated with cellular responses to TLE [18]. DLG4’s enriched function of regulating the ratio of hippocampal excitatory and inhibitory synapses suggests a connection to the symptoms of TLE (abnormal excitation); indeed, PSD-95, encoded by DLG4, is a scaffolding protein at excitatory synapses of the postsynaptic density, and downregulation of PSD-95 expression has been shown to be implicated with the onset of TLE [19] [20].

4. Conclusions

An individual is diagnosed with TLE, the most common form of focal epilepsy, when more than one temporal lobe seizure occurs and cannot be explained by another nonpermanent condition or disorder [2]. TLE can be localized to either the mesial or lateral temporal lobe; however, mesial TLE is more common (80%) compared to lateral TLE (20%). Although TLE as a whole has been proven to be influenced by genetic factors, it is currently diagnosed with EEG tests, MRI scans, and patient reports of symptoms, which can together take several months to interpret and confirm a diagnosis [3]. During this time, patients may experience additional seizures and have an increased risk for other anxiety or mood disorders, including depression [5].

This study proposes the earlier detection and diagnosis of TLE with quicker gene-based diagnostics, such as microarray and/or genetic testing or genomic heatmap analysis. It was hypothesized that candidate genes as biomarkers for the proposed diagnostic tests could be identified by analyzing gene expression patterns in the temporal lobe. Specifically, genes that were overexpressed in the temporal lobe compared to in the gray matter (≥3.000 fold change) were collected for further analysis from four donors through the Allen Human Brain Atlas. The number of genes with fold changes greater than 3.000 for the donors ranged from 145 to 330, and of these genes, 76 (29.3%) were commonly amongst the four individual donors, according to the Venny 2.1 analysis (refer to Figure 2).

When bar graphs (refer to Figure 3) were generated to depict the top twenty genes with the highest fold changes for each donor, ten genes were found to be common amongst all four bar graphs. Through further statistical analysis (refer to Table 1), it was determined that mean fold change values were directly correlated with the five number summary (minimum, quartile 1, quartile 2, quartile 3, and maximum) fold change values; the minimum fold changes, variances, and standard deviations only varied slightly from donor to donor.

The DAVID keyword analysis with the Python script (refer to Figures 4-6) revealed that the genes of interest were associated with many epilepsy-related phenomena, including inflammatory responses, excitatory postsynaptic potentials, the neurotransmitters glutamate (excitatory) and GABA (inhibitory), lipids, saccharides, neuron development and migration, and calcium concentrations. In the Gene Ontology analysis, the 76 commonly-expressed genes (from Venny 2.1) were revealed to be predominantly classified under “binding” and “catalytic activity” (Molecular Function); “cell part”, “cell”, “organelle”, and “membrane” (Cellular Component); and “cellular process”, “biological regulation”, “cellular metabolic process”, and “cell communication” (Biological Processes). “Cellular metabolic process” and “cell communication” were subcategories of the “cellular process” category. Although the categories are relatively broad, these findings suggest a possible connection to the hallmark abnormal neural excitation of TLE.

The experimental-evidence-based STRING protein interactions analysis was first conducted with the 10 genes found through the keyword search (ADCY2,HTR2A,MEF2C,CAMK2A,HTR4,SLC22A5,SERPINF1,NPY,and PRKCI). As shown in Figure 7, the clusters were mainly centered around PRKCI, MEF2C, PSMD1, CAMK2A, NPY, ADCY2, SERPINF1, and HTR2A. However, DLG4, as well as members of the MAPK and proteasome regulatory subunit groups, did seem to have an integral role in linking different clusters together. Further investigation into interactions between the original input genes and MAPK’s (refer to Figure 8 and Figure 9) not only revealed that HTR2A was indirectly associated with ACDY2 via GNAO1 and GNAI1—members of the guanine nucleotide-binding protein subunit group—but also highlighted the importance of MAPK’s in facilitating interconnectivity between different clusters. With the analysis of each gene’s STRING enriched functions, it was concluded that changes in the expression of CAMK2A, MEF2C, NPY,MAPK7, or DLG4 could potentially be biomarkers for TLE in gene-based diagnostics. These genes tended to have a high fold-change and were common to all four donors.

More specifically, underexpression of MEF2C or DLG4 could be linked with the onset of TLE. On the other hand, changes in the expression of CAMK2A, MAPK7, or NPY could signal either the onset of TLE (overexpression of MAPK7, underexpression of CAMK2A or NPY) or a biological defense response to TLE (overexpression of CAMK2A or NPY, underexpression of MAPK7). Only CAMK2A, NPY, and DLG4 have a known correlation with TLE. Though MEF2C’s and MAPK7’s correlations with TLE have yet to be proven with substantial evidence, they do have functions similar to symptoms of TLE.

Limitations and Future Directions

Limitations in this study include the list of keywords used in the DAVID keyword search. Keywords were selected based on their relevance to TLE, and due to time constraints, the number of keywords that could be used was limited, potentially decreasing the scope of the study. Additionally, the candidate genes identified could possibly overlap with genetic factors of other neurological conditions, potentially making it difficult for genomic heatmap analysis and microarray and/or genetic testing to narrow down a diagnosis to TLE. Increasing the number of donors may have also increased the accuracy of the results. The fact that data was collected from donors without a history of epilepsy is not considered a severe limitation, as the initial hypothesis was that certain genes normally overexpressed in the temporal lobe as a whole may be candidate biomarkers for TLE. Furthermore, the database of choice (Allen Human Brain Atlas) did not have gene expression profiles specific to donors only with epilepsy.

More research is required to confirm the utility of the candidate genes in genomic heatmap analysis and microarray and/or genetic testing. In addition, integrative genomic analysis studies could also be conducted to identify candidate genes common to TLE and other neurological conditions, as epilepsy is often accompanied with other neurological or psychological symptoms [1]. Another possibility may be to analyze gene expression profiles of donors of different ages, investigating whether different genes contribute to the onset of TLE at different stages in life.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] Cleveland Clinic (n.d.) Temporal Lobe Epilepsy.
[2] Beverly, J.M., Blumenrath, S., Chiu, L., Davis, A., Fessenden, M., Galinato, M., Halber, D., Hopkin, K., Kelly, D., Parks, C., Richardson, M., Rojahn, S., Sheikh, K.S., Weintraub, K., Wessel, L., Wnuk, A. and Zyla, G. (2012) Brain Facts: A Primer on the Brain and Nervous System. The Society for Neuroscience, Washington DC, 75.
[3] Klein, H. and Joshi, C. (2019) Temporal Lobe Epilepsy (TLE).
[4] Born, J., Matos, H.C., de Araujo, M.A., Castro, O.W., Duzzioni, M., Peixoto-Santos, J.E., Leite, J.P., Garcia-Cairasco, N., Paçó-Larson, M.L. and Gitaí, D. (2017) Using Postmortem hippocampi Tissue Can Interfere with Differential Gene Expression Analysis of the Epileptogenic Process. PLoS ONE, 12, e0182765.
[5] Vosburgh, S. and Obsorne Shafer, P. (2018) Overview of Depression.
[6] Gambardella, A., Manna, I., Labate, A., Chifari, R., La Russa, A., Serra, P., Cittadella, R., Bonavita, S., Andreoli, V., LePiane, E., Sasanelli, F., Di Costanzo, A., Zappia, M., Tedeschi, G., Aguglia, U., Quattrone, A. (2003) GABA(B) Receptor 1 Polymorphism (G1465A) Is Associated with Temporal Lobe Epilepsy. Neurology, 60, 560-563. https://doi.org/10.1212/01.WNL.0000046520.79877.D8
[7] Vadlamudi, L., Scheffer, I.E. and Berkovic, S.F. (2003) Genetics of Temporal Lobe Epilepsy. Journal of Neurology, Neurosurgery & Psychiatry, 74, 1359-1361.
[8] Allen Human Brain Atlas (2010) Allen Institute for Brain Science.
[9] Oliveros, J.C. (2007-2015) Venny. An Interactive Tool for Comparing Lists with Venn’s Diagrams. https://bioinfogp.cnb.csic.es/tools/venny/index.html
[10] Smithson, R. and Thomas, G. (2012) Python Anywhere.
[11] Database for Annotation, Visualization and Integrated Discovery (2003-2020) DAVID Bioinformatics Resources 6.8.
[12] The Gene Ontology Consortium (2019) The Gene Ontology Resource: 20 Years and Still GOing Strong. Nucleic Acids Research, 47, D330-D338.
[13] Harvey, V.L. and Dickenson, A.H. (2010) EPSPs and IPSPs. In: Stolerman, I.P., Ed., Encyclopedia of Psychopharmacology, Springer, Berlin, Heidelberg.
[14] Lee, M.C., Ban, S.S., Woo, Y.J. and Kim, S.U. (2001) Calcium/Calmodulin Kinase II Activity of Hippocampus in Kainate-Induced Epilepsy. Journal of Korean Medical Science, 16, 643-648. https://doi.org/10.3346/jkms.2001.16.5.643
[15] Salih, D.A. and Brunet, A. (2008). FoxO Transcription Factors in the Maintenance of Cellular Homeostasis during Aging. Current Opinion in Cell Biology, 20, 126-136.
[16] Huang, Y.Y., Wu, X.L., Guo, J. and Yuan, J.X. (2016) Myocyte-Specific Enhancer Binding Factor 2A Expression is Downregulated during Temporal Lobe Epilepsy. The International Journal of Neuroscience, 126, 786-796.
[17] Noè, F., Pool, A.-H., Nissinen, J., Gobbi, M., Bland, R., Rizzi, M., et al. (2008) Neuropeptide Y Gene Therapy Decreases Chronic Spontaneous Seizures in a Rat Model of Temporal Lobe Epilepsy. Brain, 131, 1506-1515.
[18] Badodi, S., Baruffaldi, F., Ganassi, M., Battini, R. and Molinari, S. (2015) Phosphorylation-Dependent Degradation of MEF2C Contributes to Regulate G2/M Transition. Cell Cycle, 14, 1517-1528.
[19] Coley, A.A. and Gao, W.J. (2018) PSD95: A Synaptic Protein Implicated in Schizophrenia or Autism? Progress in Neuro-Psychopharmacology & Biological Psychiatry, 82, 187-194. https://doi.org/10.1016/j.pnpbp.2017.11.016
[20] Sun, Q.J., Duan, R.S., Wang, A.H., Shang, W., Zhang, T., Zhang, X.Q. and Chi, Z.F. (2009) Alterations of NR2B and PSD-95 Expression in Hippocampus of Kainic Acid-Exposed Rats with Behavioural Deficits. Behavioural Brain Research, 201, 292-299. https://doi.org/10.1016/j.bbr.2009.02.027

Copyright © 2021 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.